Unknown PHASE2 INTERVENTIONAL 2-arm NCT04971291

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients (TARGET)

A Randomized, Active-Controlled, Evaluation of AXS-05 for the Treatment of Treatment Resistant Depression in Treatment-Adherent Patients

Sponsor: Axsome Therapeutics, Inc.

Conditions Major Depressive Disorder Treatment Resistant Depression

Interventions AXS-05 Bupropion SR

Updated 4 times since 2021 Last updated: Jul 20, 2021 Started: Apr 14, 2021 Primary completion: Jul 31, 2021 Completion: Jul 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Major Depressive Disorder and Treatment Resistant Depression and is currently ongoing. Axsome Therapeutics, Inc. leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Aug 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Enrolling By Invitation → Unknown Status
Sep 2021 — Aug 2023 [monthly]

Enrolling By Invitation PHASE2

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Axsome Therapeutics, Inc.

Data source: Axsome Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States